Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fostamatinib (Primary)
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Acronyms FOCUS
Sponsors Rigel Pharmaceuticals

Most Recent Events

11 Oct 2023 According to a Rigel Pharmaceuticals media release, the company announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical trial at IDWeek 2023 being held October 11-15, 2023, in Boston, MA.
13 Apr 2023 Last checked against ClinicalTrials.gov record.
07 Apr 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com